Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products

12 Sept 2017

Abstract excerpt

Exposure to replication-competent lentivirus (RCL) is a theoretical safety concern for individuals treated with lentiviral gene therapy. For certain ex vivo gene therapy applications, including cancer immunotherapy trials, RCL detection assays are used to screen the vector product as well as the vector-transduced cells. In this study, we reviewed T cell products screened for RCL using methodology developed in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Cytomegalovirus and herpesvirus research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28970045
DOI: 10.1016/j.ymthe.2017.09.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell ProductsPMID 28970045Read ↗

Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository ExperienceSemantic proximity Read ↗

Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology PatientsSemantic proximity Read ↗

Replication-competent Lentivirus Analysis of Clinical Grade Vector ProductsSemantic proximity Read ↗

Regulatory Considerations for Novel Gene Therapy Products: A Review of the Process Leading to the First Clinical Lentiviral VectorSemantic proximity Read ↗

Clinical use of lentiviral vectorsSemantic proximity Read ↗

Lentiviral Vectors for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety PerspectiveSemantic proximity Read ↗

A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene TherapiesSemantic proximity Read ↗

Replication-Competent Retroviruses in Gene-Modified T Cells Used in Clinical Trials: Is It Time to Revise the Testing Requirements?Semantic proximity Read ↗

Lentivirus for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety PerspectiveSemantic proximity Read ↗

Gene therapy for cancer: regulatory considerations for approvalSemantic proximity Read ↗

Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapiesSemantic proximity Read ↗

Risk and Benefit Assessment of Gene Therapy with Lentiviral Vectors and Hematopoietic Stem Cells: The Skysona CaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.